A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma
Phase of Trial: Phase I
Latest Information Update: 27 May 2017
At a glance
- Drugs SC 002 (Primary)
- Indications Neuroendocrine carcinoma; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Stem CentRx
- 24 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019.
- 24 Jun 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Jan 2019.
- 23 Jul 2015 New trial record